TABLE 1.

Characterization of the anti-RSV-A monoclonal antibodies and anti-BB-G_190–204 polyclonal serum

MAb or polyclonal seruma	Ig isotype	Pepscan reactivities (amino acid residues)b	ELISA titer (log10) vs:							In vitro neutralizing activity/25 μl
			RSV-A	BBG2Na	P40-G172–187	P40-G171–187	P40-G144–159Cys	P40-G190–204Cys	P40-G164–176
5B7 (a)	IgG1	163–174	4.58	6.25	<1.95	<1.95	<1.95	<1.95	5.53	<8
5C2 (b)	IgG1	150–157	5.77	5.77	1.95	<1.95	5.77	<1.95	<1.95	<8
6H66 (a)	IgG1	NRc	4.82	6.25	2.90	5.53	<1.95	<1.95	<1.95	<8
6H69 (a)	IgG1	NR	4.10	5.77	2.90	4.58	<1.95	<1.95	<1.95	<8
11F7 (a)	IgG1	176–187	5.29	6.73	6.25	5.29	2.43	2.19	<1.95	<8
18D1 (c)	IgG1	178–185	4.58	6.73	6.73	6.01	2.90	2.43	2.90	<8
8A3 (d)	IgG1	NDd	3.38	4.82	<1.95	<1.95	<1.95	4.34	<1.95	<8
Anti-BB-G190–204	ND	ND	5.22	6.25	1.95	<1.95	3.38	5.59	2.90	<8

^aMAbs produced by immunizing BALB/c mice with BBG2Na (a), G2ΔC (b), KLH-G1ΔCa (c), or P40-G_190–204 (d). 

^bReactivities against overlapping 8-mer peptides spanning the region containing residues 130 to 230 of the RSV-A(Long) G protein. 

^cNR, no reactivity. 

^dND, not determined.